Healio Rheumatology Current Issue
The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- Communication breakdown: Language barriers a ‘major cause’ of disparities Rob Volansky
-
- Rheumatology perspective: Will NASEM’s new long COVID definition aid diagnosis, treatment? Leonard H. Calabrese, DO
- ‘A major clue has been discovered’: Data illuminate autoimmunity gap between women and men Rob Volansky
- Belimumab triggers ‘surge’ of memory B cells in patients with lupus Justin Cooper
- CMS proposes cutting physician payments for fifth straight year Andrew (Drew) Rhoades
- ‘Common and unique immune features’ in long COVID may lead researchers to treatments Rob Volansky
- Deucravacitinib ‘very likely’ best small molecule for systemic lupus erythematosus Justin Cooper
- EULAR offers separate criteria for overall hand, thumb, interphalangeal osteoarthritis Justin Cooper
- FDA approves biosimilar Pyzchiva for all approved Stelara indications
-
- FDA approves Kevzara for polyarticular juvenile idiopathic arthritis
- Higher steroid dose improves lupus nephritis renal outcomes, raises mortality risk Justin Cooper
- JAK, IL-6 inhibition most effective targeted therapies for VEXAS syndrome Justin Cooper
- Knowing ‘fluid’ nature of axial spondyloarthritis critical to preventing serious outcomes Rob Volansky
- Lung involvement, cancer ‘two things you should always worry about’ in dermatomyositis Justin Cooper
- Major cardiac event risk in gout rises with monosodium urate deposits on CT Justin Cooper
- Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription Justin Cooper
- New EULAR guidance on patient research partners aims to overcome ‘tokenistic’ approaches Justin Cooper
-
- ‘Nobody else to see’: Families trek hundreds of miles for pediatric rheumatology visits Justin Cooper
- Paxlovid, though safe, shows no benefit in long COVID treatment Justin Cooper
- Pegloticase ‘effectively and expeditiously’ leads 47% of gout patients into remission Justin Cooper
- Recent flares, starting dose predict gout flare risk in first 6 months of allopurinol Justin Cooper
- Tofacitinib effective for juvenile idiopathic arthritis through 4 years Justin Cooper
- Fruit juice, sugar-sweetened beverages raise gout risk Justin Cooper
- Upadacitinib’s risk-benefit profile in rheumatoid arthritis ‘favorable’ through 5 years Justin Cooper